Allon Therapeutics, Inc. reported unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported a net loss of $1,071,311 or $0.01 per share compared to $2,778,704 or $0.03 per share a year ago, representing a decrease in net loss of $1,707,393.